跳至主要内容
临床试验/NCT02827032
NCT02827032招募中不适用

Controlling and Lowering Blood Pressure With the MobiusHD™ - Defining Efficacy Markers

Vascular Dynamics, Inc.42 个研究点 分布在 3 个国家目标入组 200 人开始时间: 2016年7月最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
42
主要终点
Evaluation of 24-hour systolic Ambulatory Blood Pressure Measurement (ABPM)

研究概览

简要总结

To perform post-market surveillance and evaluate the performance of the MobiusHD System in subjects with primary resistant hypertension.

详细描述

The CALM-DIEM Trial is an open-label, prospective, multicenter study for patients who have been selected for treatment with the MobiusHD.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mean 24-hour systolic ABPM is ≥130 mmHg following at least 30 days on a stable antihypertensive medication regimen (no changes in medication or dose), and no more than 28 days prior to implantation.

排除标准

  • Known or clinically suspected baroreflex failure or autonomic neuropathy
  • Substudy Eligibility Criteria: A maximum of 16 patients will be enrolled in the sub-study at one site (Universitair Medisch Centrum Utrecht)
  • Inclusion Criteria:
  • Patients must be eligible for the main study and must have passed all CALM-DIEM study inclusion and exclusion criteria at time of screening
  • Exclusion Criteria:
  • Use of anti-hypertensive drugs directly acting on the sympathetic nervous system that cannot be discontinued safely
  • Underlying conditions that prohibit microneurography, performance of a Valsalva maneuver and/or magnetic resonance imaging

结局指标

主要结局

Evaluation of 24-hour systolic Ambulatory Blood Pressure Measurement (ABPM)

时间窗: Baseline to ninety (90) days post treatment

Change in the mean 24-hours systolic Ambulatory Blood Pressure

次要结局

  • Incidence of Adverse Events(Baseline to three (3) years post treatment)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (42)

Loading locations...

相似试验